Understanding Arrow Psma Targeted Radioligand Therapy Plus Enzalutamide In Mcrpc
Exploring Arrow Psma Targeted Radioligand Therapy Plus Enzalutamide In Mcrpc reveals several interesting facts. Frédéric Pouliot, MD, PhD, FRCSC, University Hospital of Quebec and Laval University, Quebec, Canada, shares an update on ...
Key Takeaways about Arrow Psma Targeted Radioligand Therapy Plus Enzalutamide In Mcrpc
- Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, discusses the 5-year overall survival (OS) analysis from the ...
- Andrei Gafita, MD, Johns Hopkins Medicine, Baltimore, MD, discusses the real-world use of 177Lu-
- Scott Tagawa, MD, MS, of the Weill Cornell Medicine, New York City, NY, talks about the use of lutetium-177 ...
- Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medical College, New York, NY, discusses the potential benefits of 177Lu-
- Latest research, clinical trials, preclinical research and lifestyle changes that
Detailed Analysis of Arrow Psma Targeted Radioligand Therapy Plus Enzalutamide In Mcrpc
The ENZA-p Phase 2 trial explores secondary outcomes of combining [177Lu]Lu- Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, shares an update on the results ... Omid Yazdanpanah, MD, University of California, Irvine, CA, comments on the potential of
Frédéric Pouliot, MD, PhD, FRCSC, University Hospital of Quebec and Laval University, Quebec City, Quebec, discusses the ...
Stay tuned for more updates related to Arrow Psma Targeted Radioligand Therapy Plus Enzalutamide In Mcrpc.